Luna G, Alping P, Burman J, et al. - This nationwide register-based cohort study was conducted to investigate the risk of serious infections associated with disease-modifying treatments for multiple sclerosis (MS). This was performed in Sweden between January 1, 2011, and December 31, 2017. Researchers applied National registers with prospective data collection from the public health care system. They recruited a sum of 6,421 individuals (3260 taking rituximab, 1588 taking natalizumab, 1,535 taking fingolimod, and 2,217 taking interferon beta/GA), plus a comparator cohort of 42,645 individuals. Individuals with MS are at a generally improved risk of infections, and this differs by treatment. It was demonstrated that the rate of infections was lowest with interferon beta and GA; among newer treatments, off-label use of rituximab was connected with the highest rate of serious infections. In addition, the different risk profiles should inform the risk-benefit evaluations of these treatments.